International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 4 , Pages 1023-1030 , 15 March 2006

Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival

Presented in part at the Ninth Annual Scientific Meeting of the Society for Neuro-Oncology, Toronto, Canada, November 2004, and the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Atlanta, GA, October 3–7, 2004.

  • Baldassarre Stea, M.D., Ph.D.

      Affiliations

    • University of Arizona Health Sciences Center, Tucson, AZ
    • Corresponding Author InformationReprint requests to: Baldassarre Stea, M.D., Ph.D., The University of Arizona Health Sciences Center, Department of Radiation Oncology, 1501 North Campbell Avenue, Tucson, AZ 85724. Tel: (520) 694-7236; Fax: (520) 626-3141
    • ,
  • John H. Suh, M.D.

      Affiliations

    • Cleveland Clinic, Cleveland, OH
    • ,
  • Adam P. Boyd, M.S.

      Affiliations

    • Allos Therapeutics, Inc., Westminster, CO
    • ,
  • Pablo J. Cagnoni, M.D.

      Affiliations

    • Allos Therapeutics, Inc., Westminster, CO
    • ,
  • Edward Shaw, M.D.

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • REACH Study Group

Received 22 August 2005 ,Revised 11 October 2005 ,Accepted 11 October 2005.

References 

  1. Chatani M , Teshima T , Hata K , et al.  A clinical investigation   Whole brain irradiation for metastases from lung carcinoma . Acta Radiol Oncol . 1985;24:311–314
  2. Murray KJ , Scott C , Greenberg HM , et al.   A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases (A report of the Radiation Therapy Oncology Group (RTOG) 9104) . Int J Radiat Oncol Biol Phys . 1997;39:571–574
  3. Gaspar L , Scott C , Rotman M , et al.   Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials . Int J Radiat Oncol Biol Phys . 1997;37:745–751
  4. Mehta MP , Rodrigus P , Terhaard CH , et al.   Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases . J Clin Oncol . 2003;21:2529–2536
  5. Safo MK , Moure CM , Burnett JC , et al.   High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector . Protein Sci . 2001;10:951–957
  6. Wireko FC , Kellogg GE , Abraham DJ . Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors . J Med Chem . 1991;34:758–767
  7. Eichelbronner O , Sielenkamper A , D’Almeida M , et al.   Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50) . Am J Physiol . 1999;277:290–298
  8. Steffen RP . Effect of RSR13 on temperature-dependent changes in hemoglobin oxygen affinity of human whole blood . In:  Hudetz AG ,  Bruley DF editor. Oxygen transport to tissue XX . New York: Plenum Press; 1998;p. 653–661
  9. Khandelwal SR , Randad RS , Lin PS , et al.   Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation . Am J Physiol . 1993;265:1450–1453
  10. Randad RS , Mahran MA , Mehanna AS , et al.   Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents . J Med Chem . 1991;34:752–757
  11. Watson JC , Doppenberg EM , Bullock MR , et al.   Effects of the allosteric modification of hemoglobin on brain oxygen and infarct size in a feline model of stroke . Stroke . 1997;28:1624–1630
  12. Amorino GP , Lee H , Holburn GE , et al.   Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13 . Radiat Res . 2001;156:294–300
  13. Teicher BA , Ara G , Emi Y , et al.   RSR13 (Effects on tumor oxygenation and response to therapy) . Drug Dev Res . 1996;38:1–11
  14. Shaw E , Scott C , Suh J , et al.   RSR13 plus cranial radiation therapy in patients with brain metastases (Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database) . J Clin Oncol . 2003;21:2364–2371
  15. Lagerwaard FJ , Levendag PC , Nowak PJ , et al.   Identification of prognostic factors in patients with brain metastases (A review of 1292 patients) . Int J Radiat Oncol Biol Phys . 1999;43:795–803
  16. Suh JH , Stea B , Nabid A , et al.   Results from a phase III study evaluating efaproxiral as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases . J Clin Oncol . 2006;24:106–114
  17. Therasse P , Arbuck SG , Eisenhauer EA , et al.  European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada   New guidelines to evaluate the response to treatment in solid tumors . J Natl Cancer Inst . 2000;92:205–216
  18. Fleiss JL . Statistical methods for rates and proportions . 2nd ed.. New York: John Wiley & Sons; 1981;
  19. Buyse M , Piedbois P . On the relationship between response to treatment and survival time . Stat Med . 1996;15:2797–2812
  20. Tu D , Shalay K , Pater J . Adjustment of treatment effect for covariates in clinical trials (Statistical and regulatory issues) . Drug Information J . 2000;34:511–523
  21. Miller AB , Hoogstraten B , Staquet M , et al.   Reporting results of cancer treatment . Cancer . 1981;47:207–214
  22. Park JO , Lee SI , Song SY , et al.   Measuring response in solid tumors (Comparison of RECIST and WHO response criteria) . Jpn J Clin Oncol . 2003;33:533–537
  23. Dachman AH , MacEneaney PM , Adedipe A , et al.   Tumor size on computed tomography scans (Is one measurement enough?) . Cancer . 2001;91:555–560
  24. Warren KE , Patronas N , Aiken AA , et al.   Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors . J Natl Cancer Inst . 2001;93:1401–1405
  25. Nieder C , Nestle U , Walter K , et al.   Dose/effect relationships for brain metastases . J Cancer Res Clin Onc . 1998;124:346–350
  26. Anderson JR , Cain KC , Gelber RD . Analysis of survival by tumor response . J Clin Oncol . 1983;1:710–719
  27. Lin DY , Fleming TR , De Gruttola V . Estimating the proportion of treatment effect explained by a surrogate marker . Stat Med . 1997;16:1515–1527

 Sponsored by Allos Therapeutics, Inc., Westminster, Colorado.

PII: S0360-3016(05)02739-2

doi: 10.1016/j.ijrobp.2005.10.004

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 4 , Pages 1023-1030 , 15 March 2006

Article Tools

* Image Usage & Resolution